Researchers to present event-free and overall survival results from NeoALTTO trial

(American Association for Cancer Research) Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news